Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3) - 21/04/16
Craig Leonardi, MD, Saint Louis University School of Medicine, St Louis, MO, United States; Richard Langley, MD, Dalhousie University, Halifax, Nova Scotia, Canada; Andrew Blauvelt, MD, MBA, Oregon Medical Research Center, Portland, OR, United States; Kenneth Gordon, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; David Shrom, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Lisa Kerr, MS, Eli Lilly and Company, Indianapolis, IN, United States; Ivaylo Stoyko, MD, Eli Lilly and Company, Indianapolis, IN, United States; Kristian Reich, MD, Dermatologikum Hamburg, Hamburg, Germany
Le texte complet de cet article est disponible en PDF.| Supported by Eli Lilly and Company. |
Vol 74 - N° 5S1
P. AB70 - mai 2016 Retour au numéro
Article précédent
- Psychological stress and skin symptoms in college students: Results of a cross-sectional web-based questionnaire study
- Reading the signs of Reed syndrome and the need to screen for renal cancer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?